Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles

Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy. Furthermore, the delivery of therapeutic agents of any kind to PDAC in particular has been hindered by the extensive desmoplasia and resultant drug delivery challenges that accompanies these tumors. Small interfering RNA (siRNA) is a promising modality for anti-neoplastic therapy due to its precision and wide range of potential therapeutic targets. Unfortunately, siRNA therapy is limited by low serum half-life, vulnerability to intracellular digestion, and transient therapeutic effect. We assessed the ability of a peptide based, oligonucleotide condensing, endosomolytic nanoparticle (NP) system to deliver siRNA to KRAS-driven cancers. We show that this peptide-based NP is avidly taken up by cancer cells in vitro, can deliver KRAS-specific siRNA, inhibit KRAS expression, and reduce cell viability. We further demonstrate that this system can deliver siRNA to the tumor microenvironment, reduce KRAS expression, and inhibit pancreatic cancer growth in vivo. In a spontaneous KPPC model of PDAC, this system effectively delivers siRNA to stroma-rich tumors. This model has the potential for translational relevance for patients with KRAS driven solid tumors.

[1]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[2]  Kim W. Lowe,et al.  RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data , 2016, Biomarkers in medicine.

[3]  Vivek Mittal,et al.  Improving the efficiency of RNA interference in mammals , 2004, Nature Reviews Genetics.

[4]  K. Giehl.  Oncogenic Ras in tumour progression and metastasis , 2005, Biological chemistry.

[5]  M. Tsuboi,et al.  Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors , 2019, Oncotarget.

[6]  N. Hosten,et al.  Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer , 2016, Gut.

[7]  Jun Chen,et al.  Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. , 2019, Small.

[8]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[9]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[10]  B. Ozpolat,et al.  Targeted Therapies for Pancreatic Cancer and Hurdles Ahead , 2018, AntiCancer Research.

[11]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[12]  N. Svrzikapa,et al.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.

[13]  Pengyuan Yang,et al.  Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes , 2016, Theranostics.

[14]  Paula A. Oliveira,et al.  Estimation of rat mammary tumor volume using caliper and ultrasonography measurements , 2013, Lab Animal.

[15]  Jingqin Luo,et al.  Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. , 2017, Immunity.

[16]  P. M. Campbell,et al.  Oncogenic Ras and its role in tumor cell invasion and metastasis. , 2004, Seminars in cancer biology.

[17]  Marta Cascante,et al.  K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts , 2005 .

[18]  L. Ellis,et al.  Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs , 2014, Molecular Cancer Therapeutics.

[19]  Huimin Yan,et al.  Suppression of NF-κB activity via nanoparticle-based siRNA delivery alters early cartilage responses to injury , 2016, Proceedings of the National Academy of Sciences.

[20]  P. Schlesinger,et al.  Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. , 2013, ACS nano.

[21]  Eleonore Fröhlich,et al.  The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles , 2012, International journal of nanomedicine.

[22]  D Saur,et al.  Oncogenic KRAS signalling in pancreatic cancer , 2014, British Journal of Cancer.

[23]  A. Morris,et al.  Reduced stimulation of helper T cells by Ki-ras transformed cells. , 1991, Immunology.

[24]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[25]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[26]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[27]  S. Sebti,et al.  Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.

[28]  Mark J. Miller,et al.  Anti-JNK2 peptide–siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice , 2018, International journal of nanomedicine.

[29]  C. Der,et al.  Ras history , 2010, Small GTPases.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[32]  P. Kaiser,et al.  RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. , 2010, American journal of ophthalmology.

[33]  S. Segal,et al.  The effect of H-ras expression on tumorigenicity and immunogenicity of Balb/c 3T3 fibroblasts. , 1993, Immunology letters.

[34]  Murray Korc,et al.  Pancreatic cancer: Stroma and its current and emerging targeted therapies. , 2017, Cancer letters.

[35]  P. M. Campbell,et al.  K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. , 2007, Cancer research.

[36]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[37]  C. Der,et al.  Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Doki,et al.  Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer , 2015, Molecular therapy. Nucleic acids.

[39]  Andrew L. Ferguson,et al.  Investigating the optimal size of anticancer nanomedicine , 2014, Proceedings of the National Academy of Sciences.

[40]  Huimin Yan,et al.  Peptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis. , 2014, The Journal of clinical investigation.

[41]  S. Wickline,et al.  Melittin derived peptides for nanoparticle based siRNA transfection. , 2013, Biomaterials.

[42]  I. B. Borel Rinkes,et al.  Control of colorectal metastasis formation by K-Ras. , 2005, Biochimica et biophysica acta.

[43]  Marta Cascante,et al.  K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. , 2005, Cancer research.

[44]  Jun Wang,et al.  Strategies to improve tumor penetration of nanomedicines through nanoparticle design. , 2019, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[45]  Weiru Wang,et al.  Ras inhibition via direct Ras binding--is there a path forward? , 2012, Bioorganic & medicinal chemistry letters.

[46]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[47]  J. Feramisco,et al.  Microinjection of the oncogene form of the human H-ras (t-24) protein results in rapid proliferation of quiescent cells , 1984, Cell.

[48]  K. Braeckmans,et al.  The role of nanoparticle concentration-dependent induction of cellular stress in the internalization of non-toxic cationic magnetoliposomes. , 2009, Biomaterials.

[49]  Wei Wu,et al.  Effective Suppression of the Kirsten Rat Sarcoma Viral Oncogene in Pancreatic Tumor Cells via Targeted Small Interfering RNA Delivery Using Nanoparticles , 2015, Pancreas.

[50]  Wei Wu,et al.  Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[51]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[52]  K. Olive,et al.  Pancreatic cancer: why is it so hard to treat? , 2013, Therapeutic advances in gastroenterology.

[53]  Channing J Der,et al.  The dark side of Ras: regulation of apoptosis , 2003, Oncogene.

[54]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[55]  Jeffrey C. Berry,et al.  Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis. , 2018, JCI insight.

[56]  B. Seliger,et al.  Multiple Levels of MHC Class I Down‐Regulation by ras Oncogenes , 1996, Scandinavian journal of immunology.

[57]  Thomas Tuschl,et al.  siRNAs: applications in functional genomics and potential as therapeutics , 2004, Nature Reviews Drug Discovery.